quinazolines has been researched along with Diabetic Angiopathies in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ait-Aissa, K; Ali, M; Kassan, M; Matrougui, K; Trebak, M | 1 |
| Akhtar, S; Al-Khaldi, AT; Attur, S; Benter, IF; Chandrasekhar, B; Dhaunsi, GS; Sarkhou, F; Yousif, MH | 1 |
| Atsumi, T; Ishizu, A; Kusunoki, Y; Miyoshi, A; Miyoshi, H; Nakamura, A; Nakazawa, D; Shida, H; Tomaru, U; Yamada, M | 1 |
| Daiber, A; Daub, S; Gori, T; Grabbe, S; Hausding, M; Karbach, S; Klein, T; Knorr, M; Kossmann, S; Kröller-Schön, S; Münzel, T; Oelze, M; Schell, R; Scholz, A; Schuff, A; Schulz, E; Sudowe, S; Wenzel, P | 1 |
| Eriksson, JW; Foley, K; Jansson, PA; Lithell, H | 1 |
1 trial(s) available for quinazolines and Diabetic Angiopathies
| Article | Year |
|---|---|
Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Hypertension; Insulin; Male; Middle Aged; Quinazolines | 1996 |
4 other study(ies) available for quinazolines and Diabetic Angiopathies
| Article | Year |
|---|---|
Augmented EGF receptor tyrosine kinase activity impairs vascular function by NADPH oxidase-dependent mechanism in type 2 diabetic mouse.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Cytochrome b Group; Diabetes Mellitus, Type 2; Diabetic Angiopathies; ErbB Receptors; Mice; Mice, Knockout; NADPH Oxidase 4; NADPH Oxidases; Phenylephrine; Quinazolines; Tyrphostins; Vasoconstriction; Vasodilation | 2015 |
The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Angiopathies; ErbB Receptors; Hyperglycemia; Lapatinib; Male; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Phosphorylation; Primary Cell Culture; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction | 2015 |
Circulating Neutrophil Extracellular Trap Levels in Well-Controlled Type 2 Diabetes and Pathway Involved in Their Formation Induced by High-Dose Glucose.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; DNA; Dose-Response Relationship, Drug; Extracellular Traps; Glucose; Humans; Hypoglycemic Agents; Middle Aged; Neutrophils; Peroxidase; Polymers; Pyrazines; Pyrroles; Quinazolines; Risk Factors; Spiro Compounds; Time Factors | 2016 |
Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Topics: Administration, Oral; Animals; Antioxidants; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Leukocytes; Linagliptin; Lipopolysaccharides; Male; Neutrophils; Oxidative Stress; Purines; Quinazolines; Rats; Rats, Wistar; Respiratory Burst; Sepsis; Vasodilation | 2012 |